Nordic Pharma acquires Visant, plans launch of dry eye disease therapy
Click Here to Manage Email Alerts
Key takeaways:
- Nordic is acquiring Visant through a subsidiary, Amring Pharmaceuticals.
- The Lacrifill canalicular occlusive device for dry eye disease will be launched in the United States.
Nordic Pharma has acquired Visant Medical through its subsidiary Amring Pharmaceuticals.
With the acquisition, Nordic will launch and commercialize Visant’s FDA-cleared dry eye disease (DED) therapy, the Lacrifill canalicular occlusive device.
“We’re ecstatic Visant Medical selected Nordic Pharma as their partner and for the opportunity to introduce Lacrifill to the ophthalmologists and optometrists treating the over 16 million people diagnosed with DED in the U.S.,” Philip Gioia, president of the U.S. team that will launch Lacrifill, said in a press release. “Lacrifill represents an innovative and elegant form factor to occlude that should become the gold standard for preoperative patient care for those with DED.”
The Lacrifill device is intended to temporarily block tear drainage by closing the canalicular system, according to the release.
Once the device is launched in the U.S., which is expected in 2024, Nordic will look to acquire regulatory approval to make it available globally.
Read more about
Click Here to Manage Email Alerts